Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men

European Journal of Epidemiology

Volumn 15, Issue 2, 1999, Pages 99-108

  Lyles, Cynthia M ^a,c   Graham, Neil M H ^b   Astemborski, Jacquie ^a   Vlahov, David ^a   Margolick, Joseph B ^a   Saah, Alfred J ^a   Farzadegan, Homayoon ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AIDS; HIV 1; Homosexuality; Injection drug use; Progression

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; EPIDEMIC; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SURVIVAL RATE; VIRUS INFECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOCYTES, MONONUCLEAR; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; SURVIVAL RATE; VIRAL LOAD; VIREMIA;

EID: 0032978042     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007556327269     Document Type: Article

References (37)

1. + lymphocyte cell enumeration for prediction of clinical course of HIV disease: A review. J Infect Dis 1992; 165: 352-363.
2. Muñoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1992; 5: 694-700.
3. Fahey JL, Taylor JMG, Detels R, et al. The Prognostic value of cellular and scrologic markers in infection with human immunodeficiency virus type 1. NEJM 1990; 332: 166-172.
4. Enger C, Grahan N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275: 1329-1334.
5. Mellors JW, Rinaldo CR, Gupto P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
6. Katzenstein DA, Hammer JSM, Hughes MD, et al. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-1098.
7. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
8. + cell count. JAMA 1998; 279(1): 35-40.
9. 3 (ACTG 175). J Infect Dis 1998; 177: 617-624.
10. Fiscus SA, Hughes MD, Lathey JL, et al. Changes in virologie markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. J Infect Dis 1998; 177: 625-633.
11. Vlahov D, Anthony JC, Muñoz A, et al. The ALIVE study: A longitudinal study of HIV-1 infection in intravenous drug users: Description of methods J of Drug Issues 1991; 21: 759-776.
12. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126: 310-318.
13. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case for AIDS definition among adolescents and adults. MMWR CDC Surveill Summ 1992; 41: 1-19.
14. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1697-1703.
15. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988; 2: 267-272.
16. Caiaffa WT, Graham NMH, Vlahov D. Bacterial pneumonia in adult populations with HIV infection. Am J Epidemiol 1993; 138: 909-922.
17. Manoff SB, Vlahov D, Herskowitz A, et al. Human immunodeficiency virus infection and infective endocarditis among injecting drug users. Epidemiol 1996; 7: 566-570.
18. Giorgi JV, Cheng H-L, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: The Multicenter AIDS Cohort Study (MACS) experience. Clin Immunol Immunopathol 1990; 55; 173-186.
19. Margolick JB, Scott ER, Chadwick KR, et al. Comparison of lymphocyte immunophenotypes obtained from two different data acquisition and analysis systems simultaneously on the same flow cytometer. Cytometry 1992; 13: 198-203.
20. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995; 171: 305-311.
21. US Department of Health and Human Services. ACTG virology manual for HIV laboratories. Bethesda, MD: National Institute of Health, 1994: S1A-1-3; publication 94-3828.
22. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32: 732-739.
23. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: Wiley and Sons, 1992.
24. Lyles CM, Vlahov D, Farzadegan H, et al. Comparison of two HIV-1 virologic measures in HIV risk groups. J Clin Microbiol (In press).
25. Vella S, Giuliano M, Florida M, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995; 9: 51-56.
26. Spijkerman IJB, Langendam MW, Veugelers PJ, et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996; 7: 571-577.
27. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. JAMA 1994; 272: 1915-1921.
28. Solomon L, Frank R, Vlahov D, Astemborski J. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Pub Health 1991; 81: 1285-1290.
29. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues 1995; 25: 225-233.
30. Pezzotti P, Phillips, AN, Dorrucci M, et al. Category of exposure to HIV and age in progression to AIDS: Longitudinal study of 1199 people with known dates of seroconversion. Br Med J 1996; 313: 583-586.
31. Pezzotti P, Rezza G, Lazzarin A, et al. Influence of gender, age, and transmission category on the progression from HIV seroconversion to AIDS. J Acquir Immune Defic Syndr 1992; 5: 745-747.
32. Palenicek J, Nelson KE, Vlahov D, Galai N, Cohn S, Saah A. Comparison of clinical symptoms of human immunodeficiency virus disease between intravenous drug users and homosexual men. Arch Intern Med 1993; 153: 1806-1812.
33. Hoover DR, Black C, Jacobsen LP, et al. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 1993; 138: 266-278.
34. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. Am J Epidemiol 1993; 138: 925-964.
35. Kifson AR, Darow WW, Hessol NA, et al. Kaposi's sarcoma in a cohort of homosexual and bisexual men, epidemiology and analysis for cofactors. Am J Epidemiol 1990; 131: 221-231.
36. Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals. JAMA 1989; 261: 3424-3429.
37. Paxton WB, Coombs RW, McElrath MJ, Keefer MC, et al. Longitudinal analysis of quantitative virologie measures in human immunodeficiency virus-infected subjects with >400 CD4 lymphocytes: Implications for applying measurements to individual patients. J Infect Dis 1997; 175: 247-254.